Global In Vitro Diagnostics Market
A concise, independent overview of the global IVD market — its size and growth outlook, the forces driving it, how it is segmented, and the companies and technologies shaping the next decade.
The market at a glance
In vitro diagnostics (IVD) covers the tests, reagents, instruments and software used to examine samples such as blood, tissue and urine outside the body. IVD plays a critical role in disease detection, monitoring and prevention — supporting better clinical decisions and improving patient outcomes across the globe. It sits at one of the largest interfaces in medtech and pharma, and remains both a dependable cash-flow franchise for established players and a fast-moving growth platform for molecular testing, next-generation sequencing (NGS), liquid biopsy and AI-driven diagnostics.
Market outlook
The global IVD market is expected to grow steadily over the next decade.
Projected market size (USD billion)
One widely cited forecast projects the market rising from USD 117.18 billion in 2025 to USD 194.13 billion by 2035. Broader industry estimates place the 2026 global IVD market somewhere between USD 106 billion and USD 135 billion — the exact figure varies by scope and methodology, but every major source agrees on sustained, mid-single-digit annual growth.
Key market drivers
Ageing population and rising disease burden
An increasing geriatric population and the growing prevalence of chronic and infectious diseases expand the need for regular testing and monitoring.
Technological advancement and automation
Automated analysers, higher throughput and connected laboratory platforms improve accuracy, speed and cost-efficiency.
Point-of-care and rapid testing
Rising demand for near-patient and rapid tests brings diagnostics closer to the patient, from hospitals to decentralized settings.
Preventive care and early diagnosis
A growing focus on preventive healthcare and earlier detection drives adoption of screening and companion diagnostics.
Expanding healthcare infrastructure
Broader access to laboratory testing worldwide, especially in emerging markets, opens new demand for equipment and consumables.
Market segmentation
The IVD market is commonly analysed across four dimensions.
By product
- Reagents
- Instruments
- Software & services
- Consumables
By technology
- Immunochemistry
- Molecular diagnostics
- Clinical microbiology
- Hematology
- Others
By application
- Infectious diseases
- Oncology
- Cardiology
- Diabetes
- Others
By end user
- Hospitals
- Diagnostic laboratories
- Home-care settings
- Research institutes
- Others
Competitive landscape — key players
A small group of global leaders anchors most of the market. Roche holds an estimated 20% of the global IVD market, with the remaining revenue concentrated among a handful of diversified players.
Roche Diagnostics
Global leaderImmunoassay, molecular, tissue diagnostics and companion diagnostics (cobas, Ventana, Foundation Medicine). Estimated ~20% global IVD share.
Abbott
Global leaderImmunoassay, clinical chemistry, point-of-care and molecular testing (Alinity, i-STAT, Architect); expanded into cancer screening via Exact Sciences.
Danaher
Global leaderA portfolio of diagnostics brands — Beckman Coulter, Cepheid, Leica and Radiometer — spanning molecular, immunoassay, hematology and pathology.
Siemens Healthineers
Global leaderImmunoassay, molecular and point-of-care testing plus a strong bridge to diagnostic imaging (Atellica, Aptio automation).
Thermo Fisher Scientific
Global leaderMolecular diagnostics, next-generation sequencing and mass spectrometry (Ion Torrent, Oncomine), with a growing companion-diagnostics menu.
Illumina
Global leaderNext-generation sequencing platforms (NextSeq Dx, NovaSeq Dx) and NGS-based companion diagnostics.
Becton Dickinson (BD)
Global leaderHematology, flow cytometry and infectious-disease testing (BD MAX, Veritor point-of-care, FACS flow cytometry).
bioMérieux
Global leaderMicrobiology and syndromic infectious-disease testing (BioFire FilmArray, VIDAS immunoassay, VITEK microbiology).
Sysmex
Global leaderHematology, urinalysis and immunochemistry, with automated laboratory solutions (XN-Series, HISCL).
Bio-Rad Laboratories
ChallengerQuality control, droplet digital PCR (ddPCR) for ctDNA monitoring and flow cytometry (QX series, Liquichek).
Technology segments
Six technology families anchor the modern IVD landscape.
Immunoassay
Chemiluminescence, ELISA and lateral-flow platforms — the broadest installed base in high-volume hospital laboratories.
Clinical chemistry
Automated analysers covering routine biomarker panels for everyday laboratory workflows.
Molecular diagnostics
PCR, real-time qPCR, isothermal amplification and next-generation sequencing — the fastest-innovating segment.
Point-of-care testing
Near-patient and rapid antigen tests that bring results closer to the patient in decentralized settings.
Hematology & flow cytometry
Routine blood-cell analysis and cell characterization across hospital and reference laboratories.
Anatomic & digital pathology
AI-driven digital pathology now extends into companion diagnostics for oncology biomarker testing.
Trends shaping the next decade
Companion diagnostics
The fastest-growing IVD category — tests that match patients to targeted therapies. Estimated at roughly USD 10–11 billion with a 10–13% CAGR, every major oncology drug launch now pairs with at least one companion diagnostic.
Liquid biopsy & early detection
Blood-based multi-cancer early-detection tests can identify multiple tumor types earlier than standard screening, paving the way for wider adoption in cancer prevention.
AI-driven diagnostics
Digital and AI-supported workflows improve throughput, standardization and decision support across laboratory and pathology settings.
Evolving regulation
Regulators are streamlining pathways for NGS-based oncology diagnostics, which is expected to shorten time-to-market for advanced molecular tests.
Consolidation & M&A
Leading players continue to acquire specialist screening and molecular businesses to broaden their oncology and companion-diagnostics franchises.
How KombiMED fits in
With more than 25 years of experience in centralized procurement of medical equipment from Europe, KombiMED gives laboratories and healthcare providers access to this full spectrum of IVD technologies — from immunoassay and clinical chemistry to molecular diagnostics and point-of-care testing — sourced from the world’s leading manufacturers. Beyond supply, we support customers with consulting, logistics, certification and after-sales service, so you can adopt the right diagnostic technology for your market with confidence.
Sources
This overview is compiled and independently rewritten from publicly available industry analyses, including:
- Spherical Insights — Top 20 Companies, Global In Vitro Diagnostics Market 2026–2035
- Mordor Intelligence — Clinical Diagnostics Market: Companies & Competitive Landscape
- Patsnap Eureka — In Vitro Diagnostic Product Global Competitive Landscape Report 2026
Figures are indicative industry estimates and may vary by source, scope and methodology. This page is provided for general information only.